Emergency rooms across the country are seeing a troubling pattern of substances marketed as “safe” or “natural” being increasingly linked to serious injuries and deaths. Kratom is a clear example of that pattern. Once commonly sold in Louisiana convenience stores and smoke shops, it has quietly moved from retail shelves into a growing number of toxicology reports and legal discussions.
Long promoted as a natural remedy for pain, anxiety, and even opioid withdrawal, kratom is now drawing increased scrutiny as new data reveal a far more concerning reality. A recent report highlighted by U.S. News & World Report found that kratom poisonings have surged dramatically over the past decade.
As those numbers continue to climb, Louisiana’s decision to ban kratom in August 2025 is taking on new significance and raising important questions about whether the law has reduced harm or simply shifted it into a less visible and harder-to-regulate market.
Kratom Is a Growing Public Health Concern
The dangers associated with kratom are not only increasing, but they are accelerating.
Between 2015 and 2025, U.S. poison control centers documented a 1,200% increase in kratom exposure reports, with cases reaching 3,434 in 2025 alone. These figures, drawn from the Centers for Disease Control and Prevention, reflect a sharp upward trend that has intensified in recent years.
What is particularly concerning is how kratom is being used.
A growing number of kratom injury cases involve multiple substances. Recent data shows that multiple drug exposures account for approximately 38% of kratom-related incidents, and those cases are far more dangerous. When combined with other substances, the risk of serious outcomes increases dramatically.
This pattern is even more pronounced in fatal cases. Of 233 kratom-associated deaths identified, 79% involved multiple substances, most commonly opioids, benzodiazepines, and stimulants. Opioids alone were present in approximately 62% of those fatalities, highlighting how kratom is frequently used in combination with other high-risk drugs.
The real-world impact is significant. Patients exposed to multiple substances are hospitalized at nearly twice the rate of those using kratom alone and are far more likely to experience severe medical complications.
Importantly, kratom is not harmless even when used on its own. Research has shown that a portion of deaths involve mitragynine, the primary active compound in kratom, without other substances present, confirming that the drug itself can be independently dangerous.
For Louisiana lawmakers, these trends help explain the urgency behind the state’s decision to act when it did.
Louisiana’s Kratom Ban: A Proactive Step or an Ongoing Challenge?
In August 2025, Louisiana enacted a statewide ban on kratom, making it illegal to possess, sell, or distribute the substance. The move was intended to address growing safety concerns and limit access to a product that had been widely available with little oversight.
Before the kratom ban was enacted, it could be purchased in gas stations, smoke shops, and online. However, months after the ban took effect, kratom has not entirely disappeared. Instead, it may still be accessible through online retailers operating outside the state or through illegal local sales. This creates a difficult enforcement environment and raises concerns that some consumers may now be exposed to even greater risks, including contaminated or mislabeled products.
In that sense, the ban may have changed where and how kratom is sold, without fully eliminating the underlying risks.
Kratom Legal Questions Are Beginning to Emerge
As reports of injuries continue to rise, kratom is being addressed through product liability law.
Unlike regulated medications, kratom products have historically been sold without standard warnings, consistent dosing, or reliable quality control. Some have been marketed as safe or “natural” alternatives, despite evidence of serious health risks.
This raises important legal questions. When a product is sold without adequate warnings, contains undisclosed contaminants, or is marketed in a misleading manner, manufacturers and distributors may be held accountable for the resulting harm.
Louisiana’s kratom ban adds another layer of complexity. If kratom is obtained illegally or from out-of-state sellers, courts may be asked to address issues involving jurisdiction, distribution chains, and responsibility for injuries.
As with other emerging product risks, kratom litigation may play a key role in uncovering what companies knew about its dangers and whether consumers were adequately warned.
Why This Matters for Louisiana Families and Future Kratom Claims
For individuals in Louisiana and across the country, the recent surge in kratom injuries is a reminder that “natural” does not necessarily mean safe. The FDA has not approved Kratom for any medical use, and its effects can vary widely depending on the product, dosage, and whether it is used alongside other substances.
While Louisiana has taken steps to limit access, the risks associated with kratom remain, particularly as it continues to circulate through online and unregulated markets.
Kratom lawsuits are likely to follow a familiar path seen in other dangerous product litigation. What begins as scattered reports of injuries can evolve into broader investigations into manufacturing practices, marketing claims, and what companies knew about the risks.
As the evidence grows, the legal system will likely play an important role for families affected by serious injury or loss due to kratom—helping determine whether those responsible for placing these products into the marketplace can be held to answer for the harm they cause.
For individuals and families dealing with these issues, it is important to understand that legal options may be available. At Herman, Katz, Gisleson & Cain, we have handled complex, dangerous product cases and are continuing to evaluate claims involving kratom-related injuries. If you have questions about a potential case, you can contact our office online, use our live chat, or call 844-943-7626 for a confidential consultation.
